Side Effects of Contrave
The first 3 common side effects are not at all alarming, while the 2 most serious side effects each only occurred in one person:
* nausea
* constipation
* headache
* one person had a gall bladder infection
* one person had seizures
Those short-term side effects are not bad, all things considered. The jury is still out on long-term sides.
Conclusion
With FDA standards satisfied, Orexigen will attempt to file for FDA approval of Contrave by 2010, although approval is not guaranteed.
Even if Contrave is not approved, doctors and scientists believe that this particular approach could become a trend in the treatment of obesity. They believe that drugs like Contrave, which target multiple areas, are the future of obesity treatment.
Monday, July 27, 2009
Tuesday, July 21, 2009
naltrexone and bupropion combination in Contrave
Against notice was appetite stimulants Therapeutics and combines two drugs - naltrexone and bupropion. Bupropion is used to treat depression and addiction to smoking, while naltrexone is already in the treatment of addiction of opium withdrawal.
"Contrave is designed to activate a hypothalmic center in the brain associated with reduced appetite, while blocking beta-endorphin, which may be responsible for limiting weight loss. We are also studying the effects of Contrave on related central pathways associated with the rewarding nature of select high calorie foods."
Contrave is a fixed dose combination of Bupropion SR (sustained release) and tasty new formulation of naltrexone SR in a single tri-layer tablet. Raves container is designed to act on neurons in the brain with the aim of achieving appetite suppression, decreased food thirst, weight loss and sustainable.
Contrave raves in the three arms, the average decrease of visceral fat ranged from 13.7% to 16.7% after 24 weeks of treatment compared to an average reduction of 4.6% between the placebo group. In addition, the effect of Cont raves was significantly higher than that observed with one of the raves Cont individual components when administered alone. Visceral fat is located inside the abdominal cavity and around vital organs like the liver. Visceral fat accumulation, as opposed to subcutaneous fat that lies just below the skin is associated with an increased risk of cardiovascular disease and type II diabetes.
"Contrave is designed to activate a hypothalmic center in the brain associated with reduced appetite, while blocking beta-endorphin, which may be responsible for limiting weight loss. We are also studying the effects of Contrave on related central pathways associated with the rewarding nature of select high calorie foods."
Contrave is a fixed dose combination of Bupropion SR (sustained release) and tasty new formulation of naltrexone SR in a single tri-layer tablet. Raves container is designed to act on neurons in the brain with the aim of achieving appetite suppression, decreased food thirst, weight loss and sustainable.
Contrave raves in the three arms, the average decrease of visceral fat ranged from 13.7% to 16.7% after 24 weeks of treatment compared to an average reduction of 4.6% between the placebo group. In addition, the effect of Cont raves was significantly higher than that observed with one of the raves Cont individual components when administered alone. Visceral fat is located inside the abdominal cavity and around vital organs like the liver. Visceral fat accumulation, as opposed to subcutaneous fat that lies just below the skin is associated with an increased risk of cardiovascular disease and type II diabetes.
late-stage trials of Contrave experimental
Orexigen Therapy Inc. (OREX.O)said, the process of Contrave experimental weight loss drug rave step 3,almost meet their target and rise up nearly 25% of their shares.
Headquartered in San Diego and as a result of the plan to get U.S. regulatory approval in the first half of next year, the clinical criteria of significant weight loss Food and Drug Administration.
"These numbers are a drug is approved, the commercial sense," analyst Corey Davis contact details Bleichroeder Natixis said in a research note.
Orexigen said 48 percent of obese patients on a higher dose of Contrave lost at least 5 percent of their body weight, compared with 16.4 percent of those given a placebo in one trial. The same dose in another trial showed that 56.3 percent of patients achieved at least 5 percent weight loss vs. 17.1 percent of the placebo group.
"We are efficient 3 times better, said Orexigen CEO, Mike Narachi.
Contrave is a pill for antidepressant Wellbutrin, bupropion is a well-known, pending the release of naltrexone, OPIOIDOBUROKKA used to treat addiction and alcoholism.
Narachi Orexigen reason, the "quality" time for the NDA to the FDA next year has decided not to contact the rave for approval.
About 3,800 patients involved of 1 years trials.
Lower dose, weight at least 39.5 percent of patients rave 5% lose contact. Orexigen is developing three of the second dose, in order to improve the effectiveness of the test, that's not the best.
Is a weight-loss drugs, FDA guidelines, and 5% difference in body weight or placebo at the time of drug testing.
The main test of a single dose, patients, average weight loss 6.1%, placebo 1.3% - 4.8% points. In both tests was 5.2% points.
January 2007, contact Orexigen rave in absolute weight difference was 4.2 percent, announced the final results of the first stage of the experiment.
Headquartered in San Diego and as a result of the plan to get U.S. regulatory approval in the first half of next year, the clinical criteria of significant weight loss Food and Drug Administration.
"These numbers are a drug is approved, the commercial sense," analyst Corey Davis contact details Bleichroeder Natixis said in a research note.
Orexigen said 48 percent of obese patients on a higher dose of Contrave lost at least 5 percent of their body weight, compared with 16.4 percent of those given a placebo in one trial. The same dose in another trial showed that 56.3 percent of patients achieved at least 5 percent weight loss vs. 17.1 percent of the placebo group.
"We are efficient 3 times better, said Orexigen CEO, Mike Narachi.
Contrave is a pill for antidepressant Wellbutrin, bupropion is a well-known, pending the release of naltrexone, OPIOIDOBUROKKA used to treat addiction and alcoholism.
Narachi Orexigen reason, the "quality" time for the NDA to the FDA next year has decided not to contact the rave for approval.
About 3,800 patients involved of 1 years trials.
Lower dose, weight at least 39.5 percent of patients rave 5% lose contact. Orexigen is developing three of the second dose, in order to improve the effectiveness of the test, that's not the best.
Is a weight-loss drugs, FDA guidelines, and 5% difference in body weight or placebo at the time of drug testing.
The main test of a single dose, patients, average weight loss 6.1%, placebo 1.3% - 4.8% points. In both tests was 5.2% points.
January 2007, contact Orexigen rave in absolute weight difference was 4.2 percent, announced the final results of the first stage of the experiment.
New drug for weight loss in both the clinical trial.
Drugs are Contraves of appetite stimulants Therapeutics, Inc. This is a combination of two drugs: the antidepressant Wellbutrin and dependency drug naltrexone.
Contraves stomach does not work. It is the hypothalamus, the brain's central control of appetite thermostat, temperature and how the body burns energy.
He must know that people lose weight quickly after the onset of Wellbutrin treatment. However, this effect quickly dissipated, and people regain weight. This is the naltrexone is that the 4 endocrine Dennis Kim, MD, MBA, appetite stimulants, Senior Vice President of Medical Affairs.
"Naltrexone and lift in the braking effect of Wellbutrin," Kim said the investigation. "So you have a synergistic signal to the hypothalamus to reduce food intake. Weight reduction is to maintain a certain period of time. "
This sounds good in theory. But does it work?
Screening of drugs in clinical trials of obesity in the number of nearly 700 people - 90% are women, the average weight of 223 pounds. Study enrollment, all participants intensive weight loss program, including consulting, food and exercise. Two thirds of participants also considered the Contraves.
Less than 60% of participants to remain in the 56 weeks.
Intensive weight loss system has worked well. After 56 weeks, and weight loss of more than 5% of body weight - 11-16 lbs. In addition, 11% of students who completed the study lost more than 15% of body weight.
However, those who have done even better Contraves. After 56 weeks, they lost 9.3% body weight - 20-25 lbs. And more than 29%, more than 15% decrease in weight.
Nausea, usually mild or moderate and often Contraves treatment side effects. More patients with mild to moderate Contraves have headaches and constipation. All these side effects tend to occur at the beginning of the year.
Despite the side effects were not Contraves patients with worsening symptoms of depression or mental. In fact, they reported a better quality of life than other participants.
It is clear that any anti-obesity work will be to better integrate the most advanced weight loss plan. More research is to examine ways to work with Contraves less stringent procedures.
"We do not expect to strengthen the need to diet and exercise plan in order to Contraves good job," he said.
Contraves is not the only drug weight loss was genius appetite stimulants. The company is also testing a compressed Empatic combined with Wellbutrin, the seizure of the drug Zonegran. In early clinical trials, obese patients lost 10% of weight in 6 months. More research results should be the end of the year.
Waden Thomas, Ph.D., University of Pennsylvania Center for Weight and eating disorders, appetite stimulants proposed study results presented at the annual meeting of the American Diabetes Association, held in June 6.9 New Orleans .
Contraves stomach does not work. It is the hypothalamus, the brain's central control of appetite thermostat, temperature and how the body burns energy.
He must know that people lose weight quickly after the onset of Wellbutrin treatment. However, this effect quickly dissipated, and people regain weight. This is the naltrexone is that the 4 endocrine Dennis Kim, MD, MBA, appetite stimulants, Senior Vice President of Medical Affairs.
"Naltrexone and lift in the braking effect of Wellbutrin," Kim said the investigation. "So you have a synergistic signal to the hypothalamus to reduce food intake. Weight reduction is to maintain a certain period of time. "
This sounds good in theory. But does it work?
Screening of drugs in clinical trials of obesity in the number of nearly 700 people - 90% are women, the average weight of 223 pounds. Study enrollment, all participants intensive weight loss program, including consulting, food and exercise. Two thirds of participants also considered the Contraves.
Less than 60% of participants to remain in the 56 weeks.
Intensive weight loss system has worked well. After 56 weeks, and weight loss of more than 5% of body weight - 11-16 lbs. In addition, 11% of students who completed the study lost more than 15% of body weight.
However, those who have done even better Contraves. After 56 weeks, they lost 9.3% body weight - 20-25 lbs. And more than 29%, more than 15% decrease in weight.
Nausea, usually mild or moderate and often Contraves treatment side effects. More patients with mild to moderate Contraves have headaches and constipation. All these side effects tend to occur at the beginning of the year.
Despite the side effects were not Contraves patients with worsening symptoms of depression or mental. In fact, they reported a better quality of life than other participants.
It is clear that any anti-obesity work will be to better integrate the most advanced weight loss plan. More research is to examine ways to work with Contraves less stringent procedures.
"We do not expect to strengthen the need to diet and exercise plan in order to Contraves good job," he said.
Contraves is not the only drug weight loss was genius appetite stimulants. The company is also testing a compressed Empatic combined with Wellbutrin, the seizure of the drug Zonegran. In early clinical trials, obese patients lost 10% of weight in 6 months. More research results should be the end of the year.
Waden Thomas, Ph.D., University of Pennsylvania Center for Weight and eating disorders, appetite stimulants proposed study results presented at the annual meeting of the American Diabetes Association, held in June 6.9 New Orleans .
Subscribe to:
Posts (Atom)
